PT  - JOURNAL ARTICLE
AU  - Carolina Duarte Ferreira Dantas
AU  - Ana Sofia Santos
AU  - David Silva
AU  - João Eurico Reis
AU  - Paulo Calvinho
AU  - Luisa Semedo
AU  - Joao Cardoso
TI  - Lung transplant outcomes in bronchiectasis –a single center experience
AID  - 10.1183/13993003.congress-2019.PA1108
DP  - 2019 Sep 28
TA  - European Respiratory Journal
PG  - PA1108
VI  - 54
IP  - suppl 63
4099  - http://erj.ersjournals.com/content/54/suppl_63/PA1108.short
4100  - http://erj.ersjournals.com/content/54/suppl_63/PA1108.full
SO  - Eur Respir J2019 Sep 28; 54
AB  - Introduction: Lung transplant (LTx) is a recognized treatment for end stage non-cystic fibrosis bronchiectasis (BE), but precise referral criteria and outcomes is still limited.Objective and Methods: to retrospectively describe the experience in BE of the portuguese LTx center, by analyzing data of all patients (pts) undergoing LTx with diagnosis of BE between Nov. 2009 and May 2018. Survival was compared to the total cohort of LTx pts in our center and the results in literature.Results: In this period 177 LTx were performed in our center, where 20 (11,2%) of these had BE as a main diagnosis. Median age at transplantation was 42y (IQR 26) with male predominance (65%). The most common BE etiology was idiopathic (70%) and the majority had previous bronchial colonization (90%), mainly with Pseudomonas aeruginosa (75%). Median BSI score was 13 (IQR 4) and 65% of pts had “severe BE” according to FACED score. Before LTx the median FEV 1 (% predicted) was 25,5%. All LTx were bilateral, none of our pts had bronchial colonization after LTx and CLAD rate was 30%. Kaplan-Mier 1-year survival for BE was 79%, similar to 80% of the total LTx group. 5-year survival for BE kept 79%, superior to 56% of the total cohort of LTx pts, despite lack of significance (p=0,25). In the BE group 80% of pts were alive at date, with the longest survival of 8 years.Conclusion: BE accounts for 11,2% of all LTx done in our center, a distribution that is superior to ISHLT registry. Comparing to all LTx pts we recognize a good BE post-transplant outcome, with a similar survival rate at 1-year and even superior at 5-years. These results reinforce the need to referral pts with severe and end stage BE and supports the role of LTx as valuable treatment for this disease.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA1108.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).